Join thousands of students who trust us to help them ace their exams!Watch the first video
Multiple Choice
Under U.S. GAAP, the cost of research and development performed for others is capitalized and recorded as:
A
Deferred revenue
B
A receivable
C
Research and development expense
D
An intangible asset
Verified step by step guidance
1
Understand the context of the question: Under U.S. GAAP, research and development (R&D) costs are treated differently depending on whether the R&D is performed for the entity itself or for others. This question specifically addresses R&D performed for others.
Clarify the accounting treatment for R&D performed for others: When an entity performs R&D for others, the costs incurred are not expensed immediately. Instead, they are recorded as a receivable because the entity expects reimbursement from the party for whom the R&D is performed.
Review the definition of a receivable: A receivable is an asset that represents an amount owed to the entity by another party. In this case, the receivable arises because the entity has performed R&D services and expects payment for those services.
Eliminate incorrect options: Deferred revenue refers to payments received in advance for services not yet performed, which does not apply here. Research and development expense applies to R&D performed for the entity itself, not for others. An intangible asset refers to non-physical assets like patents or trademarks, which is unrelated to this scenario.
Conclude the correct accounting treatment: Based on U.S. GAAP, the cost of R&D performed for others is capitalized and recorded as a receivable, reflecting the expectation of reimbursement from the party for whom the R&D was conducted.